Retrospective analyses of false-positive 2-[18F]FDG PET/CT lymph node findings in patients with papillary thyroid cancer

Document Type : Original Article

Author

Department of Nuclear Medicine, Sanggye Paik Hospital, College of Medicine, Inje University, Seoul, South Korea

Abstract

Introduction: There are inconsistent results of studies on accuracy of 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (2-[18F]FDG-PET/CT) for cervical lymph node (LN) staging. The aim of this study is to evaluate the accuracy of 2-[18F]FDG-PET/CT in the cervical LN staging of patients with papillary thyroid cancer (PTC) and the factors associated with false-positive LNs in these patients.
Methods: A total of 234 patients with pathologically proven PTC, who underwent 2-[18F]FDG-PET/CT for staging from January 2011 to December 2014, were analyzed. The gold standard for diagnosing LN is a combination of surgical pathology and clinical follow-up. Nodal uptake with a maximum standardized uptake value (SUVmax) > 2.0 was interpreted as PET/CT-positive.
Results: The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 2-[18F]FDG-PET/CT in detecting cervical LN metastases were 42.7% (41/96), 77.7% (248/319), 36.6% (41/112), 81.9% (248/303), and 69.6% (289/415), respectively. The incidence of false-positive LN metastases was 63.4% (71 of 112 LNs). The factors significantly associated with false positives were age < 45 years old (p = 0.032) and SUVmax of the primary tumor < 4.0 (p = 0.021). In addition, false-positive LNs were correlated with a low LN SUVmax, location (central vs. lateral), and direction (ipsilateral vs. contralateral).
Conclusion: These findings suggest that cervical LN staging by 2-[18F]FDG-PET/CT in PTC patients should be more carefully assessed in patients younger than 45 years old with a primary tumor SUVmax < 4.0 or contralateral LN.

Keywords

Main Subjects

References

  1. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the united states, 1974-2013. JAMA. 2017 Apr 4;317(13):1338-1348. 
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30.
  3. Dimov RS. The effect of neck dissection on quality of life in patients with differentiated thyroid cancer. Gland Surg. 2013 Nov;2(4):219-26.
  4. Jeon MJ, Kim WG, Choi YM, Kwon H, Song DE, Lee YM, Sung TY, Yoon JH, Hong SJ, Baek JH, Lee JH, Ryu JS, Kim TY, Shong YK, Chung KW, Kim WB. Recent changes in the clinical outcome of papillary thyroid carcinoma with cervical lymph node metastasis. J Clin Endocrinol Metab. 2015 Sep;100(9):3470-7.
  5. Dong W, Horiuchi K, Tokumitsu H, Sakamoto A, Noguchi E, Ueda Y, Okamoto T. Time-varying pattern of mortality and recurrence from papillary thyroid cancer: lessons from a long-term follow-up. Thyroid. 2019 Jun;29(6):802-808. 
  6. Lang BH, Wong CK, Yu HW, Lee KE. Postoperative nomogram for predicting disease-specific death and recurrence in papillary thyroid carcinoma. Head Neck. 2016 Apr;38 Suppl 1:E1256-63.
  7. Kresnik E, Mikosch P, Gallowitsch HJ, Kogler D, Wiesser S, Heinisch M, Unterweger O, Raunik W, Kumnig G, Gomez I, Grünbacher G, Lind P. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods. Eur J Nucl Med. 2001 Jul;28(7):816-21.
  8. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koëter GH, Fidler V, Pruim J, Groen HJ. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000 Jul 27;343(4):254-61. 
  9. Kim DH, Song BI, Hong CM, Jeong SY, Lee SW, Lee J, Ahn BC. Metabolic parameters using ¹⁸F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2051-7.
  10. Oh HH, Lee SE, Choi IS, Choi WJ, Yoon DS, Min HS, Ra YM, Moon JI, Kang YH. The peak-standardized uptake value (P-SUV) by preoperative positron emission tomography-computed tomography (PET-CT) is a useful indicator of lymph node metastasis in gastric cancer. J Surg Oncol. 2011 Oct;104(5):530-3.
  11. Morita S, Mizoguchi K, Suzuki M, Iizuka K. The accuracy of (18)[F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography, ultrasonography, and enhanced computed tomography alone in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma. World J Surg. 2010 Nov;34(11):2564-9.
  12. Kim K, Shim SR, Lee SW, Kim SJ. Diagnostic values of F-18 FDG PET or PET/CT, CT, and US for preoperative lymph node staging in thyroid cancer: a network meta-analysis. Br J Radiol. 2021 Apr 1;94(1120):20201076.
  13. Shalash AM, Elahmadawy MA, Heikal SY, Amin AA, Youssef AA. Value of diffusion MRI versus [18F]FDG PET/CT in detection of cervical nodal metastases in differentiated thyroid cancer patients. Nucl Med Rev Cent East Eur. 2022;25(2):112-118.
  14. Jung JH, Kim CY, Son SH, Kim DH, Jeong SY, Lee SW, Lee J, Ahn BC. Preoperative prediction of cervical lymph node metastasis using primary tumor suvmax on 18f-fdg pet/ct in patients with papillary thyroid carcinoma. PLoS One. 2015 Dec 4;10(12):e0144152. 
  15. Chong A, Ha JM, Han YH, Kong E, Choi Y, Hong KH, Park JH, Kim SH, Park JM. Preoperative lymph node staging by FDG PET/CT with contrast enhancement for thyroid cancer: a multicenter study and comparison with neck CT. Clin Exp Otorhinolaryngol. 2017 Mar;10(1):121-128.
  16. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010 Jun;17(6):1471-4.
  17. Jeong HS, Baek CH, Son YI, Choi JY, Kim HJ, Ko YH, Chung JH, Baek HJ. Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. Clin Endocrinol (Oxf). 2006 Sep;65(3):402-7.
  18. Mitchell JC, Grant F, Evenson AR, Parker JA, Hasselgren PO, Parangi S. Preoperative evaluation of thyroid nodules with 18FDG-PET/CT. Surgery. 2005 Dec;138(6):1166-74; discussion 1174-5.
  19. Pak K, Kim SJ, Kim IJ, Kim BH, Kim SS, Jeon YK. The role of 18F-fluorodeoxyglucose positron emission tomography in differentiated thyroid cancer before surgery. Endocr Relat Cancer. 2013 Jul 4;20(4):R203-13.
  20. Kim DH, Kim SJ. Diagnostic role of F-18 FDG PET/CT for preoperative lymph node staging in thyroid cancer patients; a systematic review and metaanalysis. Clin Imaging. 2020 Sep;65:100-107.
  21. Choi WH, Chung YA, Han EJ, Sohn HS, Lee SH. Clinical value of integrated [18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the preoperative assessment of papillary thyroid carcinoma: comparison with sonography. J Ultrasound Med. 2011 Sep;30(9):1267-73.
  22. Pietrzak A, Kazmierska J, Cholewinski W. Sequential 18F-FDG PET/CT imaging parameters for differentiating benign from malignant lymph nodes in head and neck carcinoma. Hell J Nucl Med. 2017 Sep-Dec;20 Suppl:80-92.
  23. Chevrel JP, Hidden G, Lassau JP, Alexandre JH, Hureau J. Le drainage veineux et lymphatique du corps thyroïde [Venous and lymphatic drainage of the thyroid gland]. J Chir (Paris). 1965 Nov;90(5):445-63. [French] 
  24. Hoyes AD, Kershaw DR. Anatomy and development of the thyroid gland. Ear Nose Throat J. 1985 Jul;64(7):318-33.

Files

Share

How to cite

Statistics